KR940021051A - 3-step drug release sustained tablet - Google Patents

3-step drug release sustained tablet Download PDF

Info

Publication number
KR940021051A
KR940021051A KR1019930003140A KR930003140A KR940021051A KR 940021051 A KR940021051 A KR 940021051A KR 1019930003140 A KR1019930003140 A KR 1019930003140A KR 930003140 A KR930003140 A KR 930003140A KR 940021051 A KR940021051 A KR 940021051A
Authority
KR
South Korea
Prior art keywords
drug
tablet
release
layer
matrix layer
Prior art date
Application number
KR1019930003140A
Other languages
Korean (ko)
Inventor
권혁노
김철수
Original Assignee
손정삼
동아제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 손정삼, 동아제약 주식회사 filed Critical 손정삼
Priority to KR1019930003140A priority Critical patent/KR940021051A/en
Publication of KR940021051A publication Critical patent/KR940021051A/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

본 발명은 3단계로 약물을 방출하는 지속성 정제에 관한 것이다.The present invention relates to long-acting tablets that release the drug in three steps.

본 발명의 3단계 약물 방출형 지속성 정제는 초기에 신속한 약물용출작용을 나타내는 표피층, 그 이후 일정한 용출속도를 유지시키는 중간 매트릭스층 및 후기에 다시 신속한 약물용출작용을 나타내는 내부 핵층의 3층으로 구성되며, 각 층마다 일정한 양의 약물을 함유한다.The three-stage drug release sustained tablet of the present invention consists of an epidermal layer that initially exhibits rapid drug dissolution, an intermediate matrix layer that maintains a constant dissolution rate, and three layers of an inner nuclear layer that exhibit rapid drug dissolution again later. Each layer contains a certain amount of drug.

본 발명의 정제는 초기의 신속한 약물방출, 중기의 일정속도의 지속적 방출, 후기의 2차적인 신속한 방출에 이르는 3단계의 방출특성을 가짐으로써, 기존의 제제에 비하여 체내에서 신속히 유효혈중농도에 도달한 후 장시간 유효혈중농도를 유지할 수 있는 잇점이 있다.The tablet of the present invention has three stages of release characteristics, that is, rapid drug release in the early stage, continuous release at a constant rate in the middle stage, and secondary rapid release in the late stage, so that the effective blood concentration is rapidly reached in the body as compared with conventional formulations. There is an advantage that can maintain effective blood concentration after a long time.

Description

3단계 약물방출형 지속성 정제3-step drug release sustained tablet

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제2도는 본 발명에 의한 지속성 정제의 용출특성을 나타내며,2 shows the dissolution characteristics of the long-acting tablet according to the present invention,

제3도는 본 발명에 의한 지속성 정제의 pH에 따른 용출특성을 나타낸다.Figure 3 shows the dissolution characteristics of the sustained tablet according to the pH according to the present invention.

Claims (4)

3중구조의 각 층이 약물을 함유하며, 그 3중구조가 초기에 신속한 약물용출작용을 나타내는 표피층, 그 이후 일정한 약물용출속도를 유지시키는 중간 매트릭스층 및 후기에 다시 신속한 약물용출작용을 나타내는 내부 핵층(핵정)으로 이루어짐을 특징으로 하는 3단계 약물방출형 지속성 정제.Each layer of the triple structure contains a drug, the triple structure of which initially shows a rapid drug dissolution, an intermediate matrix layer that maintains a constant drug dissolution rate, and an inner nuclear layer that shows rapid drug dissolution again later. 3) drug-release sustained tablet, characterized in that consisting of). 제1항에 있어서, 매트릭스층이 매트릭스 기제로서 히드록시프로필메칠셀룰로오스, 메칠셀룰로오스, 아크릴산메타크릴산코폴리머, 에칠셀룰로오스, 폴리비닐피롤리돈, 알긴산나트륨, 폴리비닐알콜, 카르복시메칠셀룰로오스나트륨, 히드록시에칠셀룰로오스, 프탈산셀룰오스아세테이트, 프탈산히드록시프로필메칠셀룰로오스, 호박산히드록시프로필메칠셀룰로오스아세테이트, 아라비아검, 잔탄검, 구아검, 로커스트빈검, 카라야검, 왁스 중의 1종 이상을 포함함을 특징으로 하는 지속성 정제.The method of claim 1, wherein the matrix layer is hydroxypropyl methyl cellulose, methyl cellulose, methacrylate acrylic acid copolymer, ethyl cellulose, polyvinylpyrrolidone, sodium alginate, polyvinyl alcohol, sodium carboxymethyl cellulose, hydroxy Ethyl cellulose, phthalate cellulose acetate, phthalic acid hydroxypropyl methyl cellulose, succinate hydroxypropyl methyl cellulose acetate, gum arabic, xanthan gum, guar gum, locust bean gum, karaya gum, wax, characterized in that it comprises at least one Durable tablets. 제1항에 있어서, 매트릭스층이 제2항에 매트릭스 기제의 1종 이상 및 제약학적으로 허용되는 통상의 첨가제를 포함함을 특징으로 하는 지속성 정제.The tablet of claim 1, wherein the matrix layer comprises at least one of the matrix bases and pharmaceutically acceptable conventional additives in claim 2. 제1항에 있어서, 핵정을 매트릭스층으로 압축코팅하여 제조된 지속성 정제.The sustained tablet according to claim 1, which is prepared by compression coating a core tablet with a matrix layer. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930003140A 1993-03-03 1993-03-03 3-step drug release sustained tablet KR940021051A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019930003140A KR940021051A (en) 1993-03-03 1993-03-03 3-step drug release sustained tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930003140A KR940021051A (en) 1993-03-03 1993-03-03 3-step drug release sustained tablet

Publications (1)

Publication Number Publication Date
KR940021051A true KR940021051A (en) 1994-10-17

Family

ID=66912205

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930003140A KR940021051A (en) 1993-03-03 1993-03-03 3-step drug release sustained tablet

Country Status (1)

Country Link
KR (1) KR940021051A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100456933B1 (en) * 1999-12-17 2004-11-10 르 라보레또레 쎄르비에르 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100456933B1 (en) * 1999-12-17 2004-11-10 르 라보레또레 쎄르비에르 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route

Similar Documents

Publication Publication Date Title
US4863742A (en) Controlled absorption pharmaceutical composition
AU672526B2 (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
US9867791B2 (en) Method of administering amantadine prior to a sleep period
ATE66813T1 (en) DRUG FORMULATION.
AR020610A1 (en) USE OF A TYPE C METACRYLIC ACID COPOLYMER ACCORDING TO THE US NATIONAL FORMULARY USP / NF PHARMACOPEA, AS A DEGREGATION AGENT AND THE MANUFACTURING PROCEDURE OF A TABLET WITH SUCH COPOLYMER
KR890006226A (en) New drugs and methods for their preparation
AU1607302A (en) Pharmaceutical preparation comprising an active dispersed on a matrix
KR900009071A (en) Adhesive film
KR880010759A (en) Controlled release preparations
CA2136411A1 (en) Immediate Release Tablet Cores of Insoluble Drugs Having Sustained Release Coating
KR20140030158A (en) Methods and compositions for treatment of attention deficit disorder
JP2007532689A (en) Particulate oral galenical formulation for delayed and controlled release of active pharmaceutical ingredients
TNSN98229A1 (en) EXTENDED RELEASE ORAL PHARMACEUTICAL FORMULATION
WO2001080829A3 (en) Taste masking coating composition
IE880281L (en) Swellable pellets
AU2002221939A1 (en) Rapidly disintegrating tablet comprising an acid-labile active ingredient
AR013117A1 (en) A SOLID PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES A BENZOFURAN DERIVATIVE WITH ANTIARRHYTHMIC ACTIVITY ADAPTED FOR ORAL ADMINISTRATION
KR840006765A (en) Process for preparing sustained release solid dosage forms
KR100583065B1 (en) Multiparticulate pharmaceutical form with programmed and timed release and preparation method
KR940021051A (en) 3-step drug release sustained tablet
BG101884A (en) Salts of the clavulanic acid
JP2002512946A5 (en)
JPS6440423A (en) Patch for mucosa in oral cavity
EP0334014A3 (en) Substitued imidazolinones and imidazolethiones
Pearson et al. Studies on membrane-active vaginal spermicides

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination